Free Trial

DexCom, Inc. (NASDAQ:DXCM) Stake Boosted by Fifth Third Bancorp

DexCom logo with Medical background

Fifth Third Bancorp lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 21.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,347 shares of the medical device company's stock after acquiring an additional 5,553 shares during the quarter. Fifth Third Bancorp's holdings in DexCom were worth $2,438,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Versant Capital Management Inc purchased a new stake in shares of DexCom during the 4th quarter worth approximately $25,000. Riverview Trust Co increased its position in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in shares of DexCom in the 3rd quarter valued at about $57,000. Covestor Ltd boosted its position in shares of DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company's stock valued at $64,000 after purchasing an additional 335 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its stake in DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock worth $65,000 after buying an additional 265 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on DXCM shares. Oppenheimer decreased their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Leerink Partners dropped their price objective on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Canaccord Genuity Group increased their target price on shares of DexCom from $89.00 to $99.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. Wells Fargo & Company boosted their price target on DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. Finally, Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and an average target price of $99.29.

Read Our Latest Report on DexCom

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.30% of the stock is owned by corporate insiders.

DexCom Trading Up 0.9 %

DXCM traded up $0.77 on Tuesday, reaching $88.30. 3,408,033 shares of the company's stock were exchanged, compared to its average volume of 3,798,543. The company has a market cap of $34.49 billion, a price-to-earnings ratio of 52.87, a PEG ratio of 2.23 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company's 50 day moving average is $79.73 and its 200-day moving average is $76.70.

DexCom Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

See Also

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Should You Invest $1,000 in DexCom Right Now?

Before you consider DexCom, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.

While DexCom currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Nuclear Energy’s Comeback: 7 Stocks to Watch in 2025

Nuclear Energy’s Comeback: 7 Stocks to Watch in 2025

Nuclear energy is making a resurgence! Watch to find out which seven nuclear energy stocks could deliver long-term gains in the transition to cleaner energy.

Related Videos

Pelosi Bets Big on AI: Her Top 5 Stock Picks
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines